Egypt’s Ministry of Health Moves To Merck’s Molnupiravir

Egypt’s Ministry of Health Moves To Merck’s Molnupiravir

Merck has been quietly making moves worldwide to position molnupiravir as the standard early-onset, orally-administered antiviral treatment for COVID-19. TrialSite has reported that Merck’s teams are crisscrossing the globe, inking deals with governments and generic drug companies. In Vietnam, the drug is even being administered as part of a home care program in Ho Chi Minh City, similar to how ivermectin has been used in Uttar Pradesh, India, and other places. Controversially this is outside of a controlled trial. Now the Egypt Independent reports, “Egypt’s Ministry of Health and Population has started working to provide new drugs that will change coronavirus resistance by reducing the viral load.” In a statement on Friday, the ministry said that the “molnupiravir” drug reduces the viral load of the disease and that Egypt is participating in two studies by the company producing the drug.

Egypt’s existing national COVID-19 protocol includes Hydroxychloroquine, Budesonide, and several other treatments depending on the stage of infection. By last year, an Egyptian pharmaceutical company, Eva Pharma, was also producing both remdesivir and favipiravir.

The mi...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee